

Senate Bill 480

Sponsored by Senator EDWARDS (Presession filed.)

SUMMARY

The following summary is not prepared by the sponsors of the measure and is not a part of the body thereof subject to consideration by the Legislative Assembly. It is an editor's brief statement of the essential features of the measure **as introduced**.

Establishes as semi-independent state agency Clinical Research of Cannabis Board. Directs board to promote use of cannabis as treatment for medical conditions, compile information on medical use of cannabis and identify and support organizations and entities that engage in clinical research of cannabis or that administer cannabis on basis of clinical research.

A BILL FOR AN ACT

1
2 Relating to the clinical research of cannabis; creating new provisions; and amending ORS 182.454.

3 **Be It Enacted by the People of the State of Oregon:**

4 **SECTION 1. Legislative findings. The Legislative Assembly finds and declares that:**

5 (1) **Use of cannabis is an effective treatment for many medical conditions and, therefore,**
6 **cannabis should be available for use like other medications;**

7 (2) **Cannabis has a variety of medical uses that effectively address the health needs of**
8 **individual patients;**

9 (3) **Encouraging the development of a medical cannabis industry is in the public interest,**
10 **as is ensuring that cannabis will continue to be used for medical purposes;**

11 (4) **The development of a medical cannabis industry is an important aspect of providing**
12 **health care to the residents of this state; and**

13 (5) **Government involvement in the medical cannabis industry is necessary to protect**
14 **patient needs and to foster appropriate partnerships between public and private sectors.**

15 **SECTION 2. Clinical Research of Cannabis Board. (1) The Clinical Research of Cannabis**
16 **Board is established as a semi-independent state agency subject to ORS 182.456 to 182.472.**

17 (2) **The board shall consist of the following members appointed by the Governor:**

18 (a) **One member with expertise in clinical research;**

19 (b) **One member with expertise in clinical research who specializes in organic chemistry;**

20 (c) **One member with expertise in agricultural research;**

21 (d) **One member with expertise in agricultural research who specializes in botany,**
22 **genomics or plant pathology;**

23 (e) **One member with expertise in finance and economics;**

24 (f) **One member with expertise in finance and economics who is knowledgeable about in-**
25 **tellectual property law;**

26 (g) **One member with expertise in the needs of patients who suffer from medical condi-**
27 **tions that may be addressed through the medical use of cannabis;**

28 (h) **One member with expertise in the needs of patients who suffer from medical condi-**
29 **tions that may be addressed through the use of cannabis who is licensed to practice medicine**
30 **under ORS chapter 677; and**

NOTE: Matter in **boldfaced** type in an amended section is new; matter [*italic and bracketed*] is existing law to be omitted. New sections are in **boldfaced** type.

1 (i) One member who is knowledgeable about the laws of this state related to marijuana.

2 (3) A member of the board must be a resident of this state or an officer or principal
3 owner of an entity registered to do business in this state.

4 (4) In making appointments under subsection (2) of this section, the Governor shall
5 consider recommendations made by organizations that study the medicinal applications of
6 cannabis and agricultural, technological and innovative ways of achieving those applications.

7 (5) The term of office for a member is four years, but a member serves at the pleasure
8 of the Governor. Before the expiration of a term, the Governor shall appoint a successor
9 whose term begins on January 1 next following. A member is eligible for reappointment.

10 (6) If a vacancy occurs on the board, the Governor shall appoint a qualified person to
11 serve the unexpired term.

12 (7) A majority of the voting members of the board constitutes a quorum for the trans-
13 action of business.

14 (8) Official action by the board requires the approval of a majority of the voting members
15 of the board.

16 (9) The board shall elect one of its members to serve as chairperson.

17 (10) The board shall meet at times and places specified by the call of the chairperson or
18 of a majority of the voting members of the board.

19 (11) The board may adopt rules necessary for the operation of the board.

20 **SECTION 3. Initial term of membership for board members.** Notwithstanding the term
21 of office specified by section 2 of this 2015 Act, of the members first appointed to the Clinical
22 Research of Cannabis Board:

23 (1) Two shall serve for terms ending January 1, 2017;

24 (2) Two shall serve for terms ending January 1, 2018;

25 (3) Two shall serve for terms ending January 1, 2019; and

26 (4) Three shall serve for terms ending January 1, 2020.

27 **SECTION 4. Duties.** (1) The Clinical Research of Cannabis Board shall operate for the
28 purposes of:

29 (a) Promoting the use of cannabis as a treatment for medical conditions;

30 (b) Researching and compiling information on the use of different strains of cannabis to
31 meet the specific health needs of individual patients; and

32 (c) Identifying and supporting organizations and entities that:

33 (A) Engage in the clinical research of cannabis; or

34 (B) Administer cannabis on the basis of clinical research.

35 (2) The board shall create and maintain a long-term strategic plan for the development
36 of a medical cannabis industry that provides patients with medical products that meet the
37 specific health needs of individual patients. The plan must include:

38 (a) A catalog of organizations and entities identified by the board pursuant to subsection
39 (1)(c) of this section;

40 (b) A description of each organization and entity identified by the board;

41 (c) An explanation of the methodology of each organization and entity identified by the
42 board;

43 (d) A summary of the findings by each organization and entity identified by the board;

44 (e) A plan for incentivizing continued clinical research of cannabis;

45 (f) A plan for using clinical research as the basis for administering cannabis;

1 (g) A plan for the establishment of communication channels through which cultivators,
 2 patients, physicians, service professionals, researchers and legislative decision makers share
 3 data related to the medical use of cannabis; and

4 (h) A plan for educating the public about the medical benefits of cannabis.

5 **SECTION 5. Powers.** To carry out the purposes of section 4 of this 2015 Act, the Clinical
 6 Research of Cannabis Board may:

7 (1) Appoint officers and enter into agreements with consultants, agents and advisers, and
 8 prescribe their duties;

9 (2) Appear before boards, commissions, departments or other agencies of municipal or
 10 county governments or the state government;

11 (3) Procure insurance against any losses in connection with properties of the board in
 12 amounts and from insurers as may be necessary or desirable;

13 (4) Accept donations, grants, bequests and devises, conditional or otherwise, of money,
 14 property, services or other items of value, including interest, but excluding corporate stock,
 15 that may be received from a government agency or a public or private institution or person;

16 (5) Hold donations, grants, bequests and devises received under subsection (4) of this
 17 section, in accordance with the terms and conditions of the donation, grant, bequest or de-
 18 vise, for any purpose specified in sections 1 to 7 of this 2015 Act;

19 (6) Provide and pay for advisory services and technical assistance that the board finds
 20 necessary or desirable; and

21 (7) Exercise any other powers necessary for the operation and functioning of the board
 22 under sections 1 to 7 of this 2015 Act.

23 **SECTION 6. Reports.** The report submitted by the Clinical Research of Cannabis Board
 24 under ORS 182.472 must include for the most recent biennium:

25 (1) A description of the long-term strategic plan created by the board under section 4 (2)
 26 of this 2015 Act; and

27 (2) A description of the progress of the board in achieving the objectives described in
 28 section 4 (1) of this 2015 Act.

29 **SECTION 7. Rules.** In accordance with the applicable provisions of ORS chapter 183, the
 30 Clinical Research of Cannabis Board may adopt rules necessary for the administration of
 31 sections 1 to 7 of this 2015 Act.

32 **SECTION 8.** ORS 182.454, as amended by section 19, chapter 722, Oregon Laws 2013, and sec-
 33 tion 3, chapter 72, Oregon Laws 2014, is amended to read:

34 182.454. The following semi-independent state agencies are subject to ORS 182.456 to 182.472:

35 (1) The Appraiser Certification and Licensure Board.

36 (2) The State Board of Architect Examiners.

37 (3) **The Citizens' Initiative Review Commission.**

38 (4) **The Clinical Research of Cannabis Board.**

39 [(3)] (5) The State Board of Examiners for Engineering and Land Surveying.

40 [(4)] (6) The State Board of Geologist Examiners.

41 [(5)] (7) The State Landscape Architect Board.

42 (8) **The State Landscape Contractors Board.**

43 (9) **The State Board of Massage Therapists.**

44 [(6)] (10) The Oregon Board of Optometry.

45 [(7)] (11) The Oregon Patient Safety Commission.

1 **(12) The Physical Therapist Licensing Board.**

2 [(8)] **(13)** The Oregon Wine Board.

3 [(9) *The State Board of Massage Therapists.*]

4 [(10) *The Physical Therapist Licensing Board.*]

5 [(11) *The State Landscape Contractors Board.*]

6 [(12) *The Citizens' Initiative Review Commission.*]

7 **SECTION 9. Section captions. The section captions used in this 2015 Act are provided**
8 **only for the convenience of the reader and do not become part of the statutory law of this**
9 **state or express any legislative intent in the enactment of this 2015 Act.**

10